Table 1.
New drugs in HCL.
| New drugs in HCL | N | ORR (%) | CR (%) | MRD negative | PFS | OS | Relapses | Follow-up | Study |
|---|---|---|---|---|---|---|---|---|---|
| Vemurafenib | 50 | 96–100 | 35–42 | – | 73% at 1 year a | 91% at 1 year a | 27% at 1 year a | 11.7 months a | Tiacci et al. 71 |
| Rituximab + vemurafenib | 30 | 87 | 87 | 65% of CR pts | 78% | – | 15% | 37 months | Tiacci et al. 74 |
| Dabrafenib | 10 | 80 | 30 | 0% | 10% | 90% | 88% | 64 months | Tiacci et al. 73 |
| Dabrafenib + trametinib | 43 | 78 | 49 | 30% of CR pts | 98% at 1 year | 98% at 1 year | 2% | – | Kreitman et al. 75 |
| Moxetumomab pasudotox | 80 | 75 | 41 | 82% of CR pts | median 71.7 months | – | – | 24.6 months | Kreitman et al. 78 |
| Ibrutinib | 37 | 54 b | 19 b | – | 73% at 36 months | 85% at 36 months | – | 3.5 years | Rogers et al. 56 |
CR, complete response; HCL, hairy cell leukemia; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
a
In the US trial.
b
As best response at any time.